JOHANNESSEN JAN 4

What Happened Jan Johannessen, a director of Twist Bioscience (TWST), exercised derivative securities and sold shares on May 12, 2026. The Form 4 shows two exercise/conversion transactions (code M) totaling 24,000 shares acquired — 12,000 shares exercised at $14.00 per share (cost $168,000) and 12,000 shares acquired at $0.00 — and a contemporaneous open-market sale (code S) of 12,000 shares at $56.12 per share for total proceeds of $673,440. The sale followed the exercise on the same day, effectively monetizing part of the exercised/converted shares.

Key Details

• Transaction date: May 12, 2026; Form 4 filed May 14, 2026 (timely filing).
• Exercises/acquisitions: 12,000 shares @ $14.00 (paid $168,000) and 12,000 shares @ $0.00 (acquired).
• Sale: 12,000 shares sold in open market @ $56.12, proceeds $673,440.
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: F1 indicates the option vesting schedule (1/3 vested Oct 30, 2019 and 1/3 on each annual anniversary thereafter, subject to continued service).
• Transaction codes: M = option exercise/conversion; S = sale.

Context

• Because the sale occurred the same day as the exercises, this is effectively a cashless monetization of some exercised/converted shares (exercise + immediate sale). The filing is factual and does not state the insider's motivation.
• For derivative transactions, the filing confirms option vesting per the footnote; one of the acquisitions shows a $0.00 price (conversion/vesting or other derivative settlement), which can occur when shares vest or are converted without an exercise payment.